From the impact of Obamacare to cutting-edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about a potentially landmark Supreme Court ruling, the impact of President Obama's budget on health-care stocks, the next wave of innovation for the pharma industry, and why investors need to pay attention to a small research company from upstate New York.
In the following segment, health-care analyst David Williamson takes a closer look at Obama's budget. There are definite winners and losers as the administration looks to protect certain parts of the sector while hitting others as Obamacare continues its rollout.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. Follow David on Twitter: @MotleyDavid. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.